BH-2941

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBH-2941

Drug Alias NameBH-2941

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Programmed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHanmi Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A